NOK 4.43
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Established in 2017, Thor Medical ASA, with its headquarters in Oslo, Norway, specializes in the development and provision of alpha-particle emitters for oncology treatments within Norway.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Data is available to registered users only
Target Price
The average target price of TRMED.OL is 4.20 and suggests 5.3% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t
Data is available to registered users only